Decitabine for Poor Graft Function Post Allo-HSCT

NCT05907499 PHASE3 NOT_YET_RECRUITING

This randomized trial aims at validating the efficacy and safety of low-dose decitabine for PGF post allo-HSCT.

Details

Lead sponsor	The First Affiliated Hospital of Soochow University
Phase	PHASE3
Status	NOT_YET_RECRUITING
Enrolment	76
Start date	Sat Jul 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Nov 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Poor Graft Function

Interventions

• Decitabine
• Granulocyte Colony-Stimulating Factor
• Thrombopoietin Receptor Agonist
• Recombinant human erythropoietin